INTELLIGENT REFRIGERATED AUTOMATIC STORAGE SYSTEM

智能冷藏自动化仓储系统

• 批准号: 3509433
• 负责人: BYRON L NIELSON
• 金额: $ 21.99万
• 依托单位: AUTOMATED CONTROL SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 1994-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3509433
• 关键词: DVD /CD ROM; artificial intelligence; biomedical automation; biomedical equipment development; cold temperature; computer data analysis; computer human interaction; computer program /software; computer system design /evaluation; cryopreservation; information systems; laboratory accident /infection; occupational health /safety; online computer; personal computers; robotics; safety equipment

An advanced Phase II prototype for a computer-controlled Intelligent Refrigerated Automatic Storage System (IRASS) for medical laboratories will be developed. The system will build on the features of the Phase I project: a database to track storage/retrieval/discard of specimens, bar code reading for specimen identification, robotic hardware for movement of specimens. Additionally extensive safety engineering, an advanced user- friendly interface incorporating text windowing and advanced input devices, a smart loading platform, optimization of motion control, hooks for communications with laboratory computers, specimen disposition logic and fault tolerance will be provided. At the end of the Phase II trial, an extensive field evaluation will take place in an actual clinical laboratory setting. This system has the potential of reducing labor costs required for the storage/retrieval of specimens, increasing test reliability by improved specimen identification, and decreasing the risk of infection for laboratory workers. Phase II will include extensive evaluations of software and hardware necessary before market release of a sophisticated IRASS, GRANT-R01MH48759 This is a proposal for a random assignment, double-blind, placebo- controlled clinical trial of carbamazepine in 66 probable and possible AD outpatients with clinically significant behavioral disorders. The duration of study is six weeks with a 10 to 7 day screening period (run-in). Subjects will be assessed for efficacy at biweekly intervals using validated instruments by raters blind to treatment condition. A clinical monitor who is open to medication status will evaluate subjects weekly to enhance safety. Subjects originally assigned to placebo will be offered an open six week trial of medication under similar study conditions. After the six week trial, there will be an open, uncontrolled, continuation phase of 24 week's duration to assess safety, drug autometabolism, and continuing efficacy. Patients will be seen at monthly intervals for follow-up. The objective of this study is to compare carbamazepine (400 to 300 mg/d) to a placebo control in terms of efficacy and side effects in treating agitated AD patients. Measures of efficacy include the Brief Psychiatric Rating Scale (BPRS), Clinical Global Improvement Scale (CGI), Hamilton Rating Scale for Depression, Relatives' Assessment of Global Symptomatology-Elderly (RAGS-E), the Physical Self-Maintenance Scale and Instrumental Activities of Daily Living (PSMS/IADL). The primary criterion for clinical response is a > 30% improvement on the agitation factor of the BPRS, and a 'much improved' rating on the CGI. A minimum effect size for carbamazepine is defined (r=0.18). A secondary objective is to replicate a prior observation that platelet 3H- imipramine binding B max is decreased, and MAO activity is relatively decreased in Alzheimer's patients with symptomatic behaviors compared to Alzheimer's disease patients without symptomatic behaviors.

高级II期原型，用于计算机控制的智能 用于医疗实验室的冷藏自动存储系统（IRASS）将 被开发。 该系统将建立在第I阶段的功能的基础上 项目：跟踪标本的存储/检索/丢弃的数据库，bar 标本识别的代码读数，机器人硬件的运动 标本。 此外，高级用户还广泛的安全工程 - 包含文本窗口和高级输入设备的友好界面， 一个智能的加载平台，优化运动控制，挂钩 与实验室计算机，标本处置逻辑和 将提供容错。 在第二阶段试验结束时， 实际的临床实验室将进行广泛的现场评估 环境。 该系统具有降低所需人工成本的潜力 对于标本的存储/检索，通过 改善了标本识别，并降低了感染的风险 实验室工人。 第二阶段将包括对 在市场释放先进的市场之前必需的软件和硬件 伊拉斯， Grant-R01MH48759 这是一个随机分配，双盲，安慰剂的建议 - 在66种可能的AD中，卡马西平的对照临床试验 患有临床上重要行为障碍的门诊病人。 持续时间 研究时间为六个星期，筛查期为10至7天（跑步）。 将在每两周一次的间隔内评估受试者的功效 对评估者验证的工具对治疗状况视而不见。 临床 监视谁对药物状态持开放态度将每周评估受试者 提高安全性。 最初分配给安慰剂的受试者将提供 在类似的研究条件下开放六周的药物试验。 后 为期六周的试验将有一个开放的，不受控制的延续阶段 24周的持续时间以评估安全性，毒品自代代谢和继续 功效。 将每月间隔观察患者以进行随访。 这项研究的目的是比较卡马西平（400至300 mg/d） 在治疗方面的功效和副作用方面进行安慰剂控制 激动的AD患者。 疗效的度量包括简短的精神病学 评分量表（BPRS），临床全球改进量表（CGI），汉密尔顿 抑郁症的评分量表，亲戚对全球的评估 症状学 - 埃尔德利（rags-e），身体自我维护量表和 日常生活的乐器活动（PSMS/IADL）。 主要标准 对于临床反应，对搅拌因子的提高> 30％ BPR和CGI的“改进”评级。 最小效应大小 定义卡马西平（r = 0.18）。 次要目标是复制先前的观察结果，即血小板3H- 丙咪嗪结合B max降低，MAO活性相对较低 与阿尔茨海默氏症患者有症状行为的患者相比有所减少 阿尔茨海默氏病患者没有症状行为。